A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation

Author： Cahill Kate   Stead Lindsay   Lancaster Tim  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.32, Iss.2, 2009-01, pp. : 119-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Preliminary Benefit-Risk Assessment of Verteporfin in Age-Related Macular Degeneration

By Wickens Jason   Blinder Kevin J.  

Drug Safety, Vol. 29, Iss. 3, 2006-01 ,pp. : 189-199

Adis International

Access to resources Recommend Favorite

Varenicline: progress in smoking cessation treatment

By Glover Elbert D   Rath Jessica M  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1757-1767

Informa Healthcare

Access to resources Recommend Favorite

Varenicline: A Novel Pharmacotherapy for Smoking Cessation

By Jiménez-Ruiz Carlos  

Drugs, Vol. 69, Iss. 10, 2009-07 ,pp. : 1319-1338

Adis International

Access to resources Recommend Favorite

A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection

By Zoulim F.  

Drug Safety, Vol. 25, Iss. 7, 2002-01 ,pp. : 497-510

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†

By Keating Gillian M.   Lyseng-Williamson Katherine A.  

CNS Drugs, Vol. 24, Iss. 9, 2010-09 ,pp. : 797-800

Adis International

Access to resources Recommend Favorite